The International AIDS Society HIV Cure Resource Tracking group joined with the HIV Vaccines and Microbicides Tracking Working Group to estimate global investments in HIV cure research and produce this short report.
Global Investment in HIV Cure Research and Development in 2013
Creating a Prevention Agenda for Women: AVAC/CHANGE meeting for coordinated global advocacy
This report, released by CHANGE and cosponsored by AVAC, summarizes the key recommendations related to integration of HIV and family planning services, how to best move forward in the context of uncertainty about whether some hormonal contraceptives (HC) increase HIV risk, and how to advance “method mix”—a wider array of contraceptive choices for women everywhere.
PrEP for Black Gay and Bi-sexual Men in the US: What you need to know
This factsheet includes information on accessing and paying for PrEP, side effects and outlines key information on the relevance of PrEP for Black gay and bisexual men.
HIV Prevention Research & Development Investment in 2013: In a changing global development, economic and human rights landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The report shows that investment in HIV prevention research fell 4 percent in 2013, due to a combination of factors including declining investments by the United States and European donors, changes in the international development landscape and changes in the pipeline of HIV prevention products being tested.
When do you stop an HIV prevention trial for futility? A primer for HIV prevention advocates
This fact sheet looks at why trials are stopped early for “futility.” What does this mean, when is such a recommendation made and how does it affect other ongoing trials?
Jeff McConnell Memorial Webinar – Audio
This webinar memorialized pioneering sociologist Jeff McConnell and his impact on HIV prevention science. Updates were presented on pre-exposure prophylaxis (PrEP) research and the implications of Dr. McConnell’s research on sexual networks for how PrEP will be implemented.Find details, slides and full flash webinar here.
HIV Prevention Europe Webinars: Rectal microbicides
The seventh webinar in our series addressing a range of topics in HIV prevention research, hosted jointly by NAM and AVAC, focused on rectal microbicides. Speakers included: Ian McGowan, University of Pittsburgh; Carolina Herrera, Imperial College; Alex Carballo-Dieguez, Columbia University; and Marc-André LeBlanc, IRMA.
The presentation was followed by a Q&A session. Click here for slides and audio from the webinar.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PrEP” trials
This 2005 report examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.
Understanding the Results of the AIDSVAX Trial
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Multipurpose Prevention Technologies for Reproductive Health
In May 2011, AVAC, USAID and CAMI convened a group of scientists to discuss and recommend strategies for accelerating the development of multipurpose prevention technologies for protection against unintended pregnancy, HIV and other STIs. This report includes the presentations and discussions from the meeting, as well as recommendations for next steps.